vs
Amphastar Pharmaceuticals, Inc.（AMPH）とDigital Turbine, Inc.（APPS）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $151.4M、Digital Turbine, Inc.の約1.2倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 3.4%、差は10.0%）。Digital Turbine, Inc.の前年同期比売上増加率が高い（12.4% vs -1.8%）。過去8四半期でDigital Turbine, Inc.の売上複合成長率が高い（16.2% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
デジタルタービン社はグローバルな広告テクノロジー企業で、モバイル通信事業者、端末メーカー、アプリ開発者向けに、アプリ収益化、ユーザー獲得、ターゲティング広告の一括ソリューションを提供しています。事業は北米、欧州、アジア太平洋地域に展開し、通信、モバイルテクノロジー、消費者向けアプリなどの分野の顧客に対応しています。
AMPH vs APPS — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $151.4M |
| 純利益 | $24.4M | $5.1M |
| 粗利率 | 46.8% | 57.4% |
| 営業利益率 | 19.4% | 14.3% |
| 純利益率 | 13.3% | 3.4% |
| 売上前年比 | -1.8% | 12.4% |
| 純利益前年比 | -35.7% | 122.1% |
| EPS（希薄化後） | $0.51 | $0.03 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $151.4M | ||
| Q3 25 | $191.8M | $140.4M | ||
| Q2 25 | $174.4M | $130.9M | ||
| Q1 25 | $170.5M | $119.2M | ||
| Q4 24 | $186.5M | $134.6M | ||
| Q3 24 | $191.2M | $118.7M | ||
| Q2 24 | $182.4M | $118.0M | ||
| Q1 24 | $171.8M | $112.2M |
| Q4 25 | $24.4M | $5.1M | ||
| Q3 25 | $17.4M | $-21.4M | ||
| Q2 25 | $31.0M | $-14.1M | ||
| Q1 25 | $25.3M | $-18.8M | ||
| Q4 24 | $38.0M | $-23.1M | ||
| Q3 24 | $40.4M | $-25.0M | ||
| Q2 24 | $37.9M | $-25.2M | ||
| Q1 24 | $43.2M | $-236.5M |
| Q4 25 | 46.8% | 57.4% | ||
| Q3 25 | 51.4% | 55.1% | ||
| Q2 25 | 49.6% | 55.6% | ||
| Q1 25 | 50.0% | 55.4% | ||
| Q4 24 | 46.5% | 48.0% | ||
| Q3 24 | 53.3% | 52.6% | ||
| Q2 24 | 52.2% | 52.7% | ||
| Q1 24 | 52.4% | 52.3% |
| Q4 25 | 19.4% | 14.3% | ||
| Q3 25 | 13.2% | 4.7% | ||
| Q2 25 | 24.2% | -3.6% | ||
| Q1 25 | 21.9% | -9.8% | ||
| Q4 24 | 24.2% | -9.5% | ||
| Q3 24 | 29.8% | -11.4% | ||
| Q2 24 | 30.3% | -13.6% | ||
| Q1 24 | 27.9% | -185.2% |
| Q4 25 | 13.3% | 3.4% | ||
| Q3 25 | 9.0% | -15.2% | ||
| Q2 25 | 17.8% | -10.8% | ||
| Q1 25 | 14.8% | -15.8% | ||
| Q4 24 | 20.4% | -17.2% | ||
| Q3 24 | 21.1% | -21.0% | ||
| Q2 24 | 20.8% | -21.3% | ||
| Q1 24 | 25.1% | -210.7% |
| Q4 25 | $0.51 | $0.03 | ||
| Q3 25 | $0.37 | $-0.20 | ||
| Q2 25 | $0.64 | $-0.13 | ||
| Q1 25 | $0.51 | $-0.18 | ||
| Q4 24 | $0.74 | $-0.22 | ||
| Q3 24 | $0.78 | $-0.24 | ||
| Q2 24 | $0.73 | $-0.25 | ||
| Q1 24 | $0.81 | $-2.33 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $40.2M |
| 総負債低いほど良い | $608.7M | $355.0M |
| 株主資本純資産 | $788.8M | $194.6M |
| 総資産 | $1.6B | $858.2M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 1.82× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $40.2M | ||
| Q3 25 | $276.2M | $38.8M | ||
| Q2 25 | $231.8M | $33.4M | ||
| Q1 25 | $236.9M | $39.4M | ||
| Q4 24 | $221.6M | $34.6M | ||
| Q3 24 | $250.5M | $32.1M | ||
| Q2 24 | $217.8M | $35.0M | ||
| Q1 24 | $289.6M | $32.9M |
| Q4 25 | $608.7M | $355.0M | ||
| Q3 25 | $608.6M | $396.4M | ||
| Q2 25 | $607.7M | $400.5M | ||
| Q1 25 | $603.9M | $408.7M | ||
| Q4 24 | $601.6M | $408.2M | ||
| Q3 24 | $596.4M | $407.6M | ||
| Q2 24 | $586.9M | $393.8M | ||
| Q1 24 | $594.0M | $383.5M |
| Q4 25 | $788.8M | $194.6M | ||
| Q3 25 | $776.7M | $148.1M | ||
| Q2 25 | $757.5M | $152.3M | ||
| Q1 25 | $751.3M | $154.0M | ||
| Q4 24 | $732.3M | $163.6M | ||
| Q3 24 | $727.7M | $182.4M | ||
| Q2 24 | $713.3M | $196.0M | ||
| Q1 24 | $672.4M | $213.9M |
| Q4 25 | $1.6B | $858.2M | ||
| Q3 25 | $1.7B | $818.7M | ||
| Q2 25 | $1.6B | $818.4M | ||
| Q1 25 | $1.6B | $812.9M | ||
| Q4 24 | $1.6B | $839.7M | ||
| Q3 24 | $1.5B | $844.5M | ||
| Q2 24 | $1.5B | $860.2M | ||
| Q1 24 | $1.6B | $865.5M |
| Q4 25 | 0.77× | 1.82× | ||
| Q3 25 | 0.78× | 2.68× | ||
| Q2 25 | 0.80× | 2.63× | ||
| Q1 25 | 0.80× | 2.65× | ||
| Q4 24 | 0.82× | 2.50× | ||
| Q3 24 | 0.82× | 2.24× | ||
| Q2 24 | 0.82× | 2.01× | ||
| Q1 24 | 0.88× | 1.79× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $14.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | — |
| FCFマージンFCF / 売上 | 13.4% | — |
| 設備投資強度設備投資 / 売上 | 4.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 2.78× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $14.2M | ||
| Q3 25 | $52.6M | $14.5M | ||
| Q2 25 | $35.6M | $8.8M | ||
| Q1 25 | $35.1M | $11.9M | ||
| Q4 24 | $29.0M | $10.4M | ||
| Q3 24 | $60.0M | $-8.7M | ||
| Q2 24 | $69.1M | $-1.4M | ||
| Q1 24 | $55.3M | $28.7M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 1.35× | 2.78× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
APPS
| On Device Solutions | $99.6M | 66% |
| App Growth Platform | $52.6M | 35% |
